ABY-1220
Alzheimer's Disease
PreclinicalActive
Key Facts
About Abyssinia Biologics
Abyssinia Biologics is a preclinical-stage biotech developing highly selective monoclonal antibodies and a vaccine targeting toxic amyloid-beta oligomers for Alzheimer's disease. Founded in 2021 and operating with a virtual team, the company's platform aims to deliver greater clinical benefit with fewer side effects, such as ARIA, compared to plaque-clearing therapies. Its integrated strategy includes therapeutic, preventative, and diagnostic solutions, positioning it in the high-need, high-value neurodegenerative disease market, though it faces significant scientific, clinical, and competitive risks typical of early-stage CNS drug development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |